BriaCell Therapeutics Announces Hiring of CFO Gadi Levin; AGM Results

BERKELEY, CA & VANCOUVER, BC – Thursday February 11th 2016: BriaCell Therapeutics Corp (OTCQB:BCTXF) (TSXV: BCT) (“BriaCell”, the “Company”, or “BCT”), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, BriaVaxTM, is pleased to announce that it has hired Mr. Gadi Levin, CPA, MBA, as the Company’s new CFO. Mr. Levin is a highly experienced …

BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. November 4, 2015 11:01 AM BERKELEY, CA and VANCOUVER, BC–(Marketwired – November 04, 2015) – BriaCell Therapeutics Corp (BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company’s Investigational New Drug (IND) application to …

BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax™ Phase I/IIa Clinical Trial

October 8, 2015 Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; Contract Negotiations Underway With Initial Clinical Site. BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase …

BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)

Mon Sep 14, 2015 9:30am EDT BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM) Also Provides General Corporate Update Including Consolidation of Its Corporate Headquarters and Research Laboratories in San Francisco Bay Area; Attends NYC Biotechnology Conference and Posts Updated Investor Presentation VANCOUVER, BC–(Marketwired – September 14, 2015) – BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX …

Skip to content